Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Though INCYs performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise…
75,830$
-2,44%
Echtzeit-Aktienkurs Incyte Corp.
Bid:
Ask:
Nachrichten zur Incyte Corp. Aktie
Kurs von Incyte steigt etwas (59,4900 €)
Das Wertpapier von Incyte notiert am Montag etwas fester. Der jüngste Kurs betrug 66,16 US-Dollar. An der US-amerikanischen Börse hat…
Incyte’s CDK2 Inhibitor INCB123667 zeigt vielversprechende Anzeichen von klinischer Wirkung bei Patienten mit soliden Tumoren in fortgeschrittenem Stadium
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) hat heute neue klinische Daten über INCB123667 bekannt gegeben, einen hochgradig selektiven, potenziellen First-in-Class-CDK2 Inhibitor für…
Incyte gibt positive Topline-Ergebnisse der Pivotalstudie mit Tafasitamab (Monjuvi®) bei rezidiviertem oder refraktärem follikulärem Lymphom bekannt
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) gab heute positive Ergebnisse der zulassungsrelevanten Phase-3-Studie inMIND bekannt, in der die Wirksamkeit und Sicherheit…
Incytes Monjuvi meets primary endpoint in follicular lymphoma phase 3 trial
…
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
On Incytes (INCY) second-quarter 2024 earnings call, investors focus is likely to be on the sales performance of its lead…
Incyte drops as BMO downgrades on $2B buybacks
…
Incyte shares slip after BMO analysts cut rating of drugmaker By Investing.com
Incyte shares slip after BMO analysts cut rating of drugmaker…
Incyte-Aktie legt um 1,33 Prozent zu (59,6756 €)
An der US-amerikanischen Börse liegt der Anteilsschein von Incyte gegenwärtig im Plus. Zuletzt zahlten Investoren für das Wertpapier 64,06 US-Dollar.…
Incyte a new hold at Deutsche Bank as key drugs approach patent cliffs
…
Incyte, Squarespace rise; Chimera Investment, Amazon fall, Monday, 5/13/2024
Stocks that are trading heavily or have substantial price changes on Monday: Incyte, Squarespace rise; Chimera Investment, Amazon fall…
Incyte shares dip after earnings, guidance miss By Investing.com
Incyte shares dip after earnings, guidance miss…
Incyte earnings missed by $0.18, revenue fell short of estimates By Investing.com
Incyte earnings missed by $0.18, revenue fell short of estimates…
Incytes (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Incytes (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.…
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.…
Incyte (INCY) to Report Q1 Earnings: Whats in the Cards?
Incytes (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on…
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”…
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
Incytes (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.…
Jefferies starts Incyte stock with Buy, cites product lineup By Investing.com
Jefferies starts Incyte stock with Buy, cites product lineup…
Incyte misses quarterly profit estimates due to higher costs By Reuters
Incyte misses quarterly profit estimates due to higher costs…
Incyte earnings missed by $0.08, revenue was in line with estimates By Investing.com
Incyte earnings missed by $0.08, revenue was in line with estimates…
Incyte (INCY) Lags Q4 Earnings and Revenue Estimates
Incyte (INCY) delivered earnings and revenue surprises of -12.40% and 0.74%, respectively, for the quarter ended December 2023. Do the…
Incytes (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
Incytes (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time…
Incyte (INCY) to Report Q4 Earnings: Whats in the Cards?
On Incytes (INCY) fourth-quarter 2023 earnings call, investors focus is likely to be on the sales performance of its lead…
Pharmakonzern: Novartis schluckt Biotechfirma Morphosys für 2,7 Milliarden Euro
Insidern zufolge hat der Pharmakonzern sich gegen den Arzneimittelhersteller Incyte durchgesetzt, der Vertriebspartner von Morphosys ist und ebenfalls um die Firma…
Pharmakonzern: Novartis kauft deutsche Biotechfirma Morphosys für 2,7 Milliarden Euro
Der Pharmariese hat sich einem Bericht zufolge gegen den Arzneimittelhersteller Incyte durchgesetzt. Novartis will den Zukauf bereits im ersten Halbjahr…
Incyte buys global rights for tafasitamab from MorphoSys
…
Incyte secures global rights to lymphoma drug tafasitamab By Investing.com
Incyte secures global rights to lymphoma drug tafasitamab…
Incyte (INCY) Banks on Opzelura as Jakafi Faces Competition
Incyte (INCY) is likely to rebound in 2024 on the solid growth of Opzelura and additional label expansions.…
Why did Incyte stock go up today? Positive drug study
…
Blitz-Update: Dow & Co legen weiter zu, IBM, Salesforce, American Express, Incyte, Icosavax, Seagen und Coinbase stark, Intel, Oracle, Tesla und Moderna schwach
Die US-Inflationsdaten für November haben die Indizes am Dienstag kaum bewegt. Sie lagen im Rahmen der Erwartungen. Die Indizes tendieren…
BUSINESS WIRE: Incyte und Syndax präsentieren bei ASH-Plenarsitzung weitere Daten aus positiver AGAVE-201-Studie, die die Wirksamkeit von Axatilimab zeigen, einschließlich dauerhaftem Ansprechen bei chronischer Graft-versus-Host-Krankheit
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.- Die Studie erreichte ihren primären Endpunkt…
Incyte: Rating gesenkt
New York (www.aktiencheck.de) - Rating-Update:
Salveen Richter, Analystin von Goldman Sachs, stuft die Aktie des US-biopharmazeutischen Unternehmens Incyte Corp. (ISIN: US45337C1027,…
Goldman Sachs cuts Incyte to hold, cites Jakafi outlook uncertainty
…
BCTX: Year in Review
By John Vandermosten, CFA
NASDAQ:BCTX
READ THE FULL BCTX RESEARCH REPORT
Fiscal Year 2023 Operational and Financial Results
On October 25th 2023, BriaCell Therapeutics…
Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates
Incytes (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance…
Incyte (INCY) to Report Q3 Earnings: Whats in the Cards?
Higher sales of lead drug Jakafi and incremental sales of newly approved drugs are likely to have boosted Incytes (INCY)…
BUSINESS WIRE: Incyte kündigt neue Daten aus dem gesamten Onkologie-Portfolio zur Präsentation auf dem ESMO-Kongress 2023 an
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.WILMINGTON, Delaware, USA --(BUSINESS WIRE)-- 16.10.2023 --Incyte…
Incyte (INCY) Stock Plummets 29.6% Year to Date: Heres Why
Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.…
BUSINESS WIRE: Incyte präsentiert positive 52-Wochen-Daten aus Phase-2b-Studie zur Evaluierung von Povorcitinib (INCB54707) bei Patienten mit großflächiger, nicht segmentaler Vitiligo
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.– Längerfristige Anwendung von Povorcitinib bewirkt weitere…
BUSINESS WIRE: Incyte präsentiert mehrere Studien zu seinem Dermatologie-Portfolio auf dem European Academy of Dermatology and Venereology (EADV) Congress 2023
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.WILMINGTON, Delaware, USA --(BUSINESS WIRE)-- 30.09.2023 --Wie…
Aktie von Incyte: Kurs mit wenig Bewegung (56,1088 €)
Im US-amerikanischen Wertpapierhandel ist das Wertpapier von Incyte derzeit unauffällig. Das Wertpapier notiert aktuell bei 58,94 US-Dollar. Wenig getan hat…
Warm Autoimmune Hemolytic Anemia Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Leading Companies - Zenas BioPharma, Sanofi, Johnson & Johnson, Novartis, Incyte, Rigel, Alpine Immune Sciences, Hutchison
The dynamics of the warm autoimmune hemolytic anemia market are anticipated to change in the coming years owing to the…
Aktienmarkt: Aktie von Incyte tritt auf der Stelle (54,9956 €)
Der Kurs der dem Anteilsschein von Incyte kommt kaum von der Stelle. Zuletzt zahlten Investoren für die Aktie 58,22 US-Dollar.…
Sjogrens Syndrome Market Size Increase with Significant CAGR by 2032, Predicts DelveInsight | Key Companies in the Market - Resolve, MorphoSys, Novartis, GlaxoSmithKline, Roche, BMS, TearSolutions, Incyte, Galapagos, Gilead Sciences
Sjogrens syndrome market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies,…
Incyte ends agreement with Syros on blood cancer treatments
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-Q INCYTE CORP For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended…
Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates
Incyte (INCY) reports impressive Q2 earnings on strong uptake in Jakafi and Opzelura sales. The company raises the bottom end…
Incyte (INCY) Beats Q2 Earnings and Revenue Estimates
Incyte (INCY) delivered earnings and revenue surprises of 13.79% and 3.74%, respectively, for the quarter ended June 2023. Do the…